Autor(es):Mostrar menos -

Carvalho, Gabriela C. ; Domingues, Maria Nolasco Viseu ; Marena, Gabriel Davi ; Makila, Ermei ; Li, Jiachen ; Geertsema-Doornbusch, Gesinda ; de Andrade, Cleverton Roberto ; Stuart, Marc C. A. ; Shahbazi, Mohammad-Ali ; Correa, Ione ; Peterson, Brandon W. ; Salonen, Jarno ; Florindo, Helena F. ; Bauab, Tais Maria ; Chorilli, Marlus ; Santos, Helder A.

• Tipo de documento: Artigo Científico
• Fonte: ADVANCED THERAPEUTICS; v. N/A, p. 19-pg., 2024-09-27.

Resumo

Vulvovaginal candidiasis represents a public health challenge due to its reports of high incidence and recurrence. These are caused by host-related factors like compromised immune system, or pathogen-related factors, such as resistance to antifungal agents, making this medical problem desirable to develop new therapeutic options. In this context, natural origin substances like curcumin, are increasingly treatment alternatives. However, some curcumin properties limit its therapeutic application, such as insolubility in aqueous solvents, which leads to low bioavailability. Nevertheless, nanotechnology association with drugs of plant origin proves to be a promising alternative to overcome the reported drawbacks. Despite being caused by a fungus, patients suffer significantly from the inflammation resulting from this disease, thus this study aimed to develop a hybrid carrier nanoformulation by microfluidics loaded with two drugs, benzydamine hydrochloride (an anti-inflammatory drug) and curcumin (an antifungal drug). Transmission electron cryomicroscopy combined with energy dispersive X-ray analysis confirmed that the nanoparticle is properly developed. Through in vitro biological studies, it is possible to observe that, in addition to being safe, the encapsulation of both drugs in the nanocarrier drastically reduced their cytotoxicity. Finally, although the final nanoformulation does not show in vitro activity, the in vivo study indicated therapeutic potential. This study offers new possibilities for the development of silica-based hybrid nanoparticles by microfluidics and highlights the potential combination of curcumin and benzydamine hydrochloride for the treatment of vulvovaginal candidiasis. This disease is a public health challenge due to its reports of high incidence, recurrences and resistance to antifungal agents, making it desirable to develop new therapeutic options. image (AU)

• Processo FAPESP: 22/02187-0 - Sistema nano-in-nano contendo curcumina e cloridrato de benzidamina para o tratamento da candidíase vulvovaginal: do desenvolvimento à aplicação in vitro anti-inflamatória
• Beneficiário: Gabriela Corrêa Carvalho
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 19/26821-7 - Nano-in-nano contendo curcumina e cloridrato de benzidamina para tratamento de Candidíase Vulvovaginal: do desenvolvimento à aplicação biológica in vitro e in vivo
• Beneficiário: Gabriela Corrêa Carvalho
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 19/09831-9 - Nanoemulsões para co-encapsulação de anfotericina B e micafungina: desenvolvimento, caracterização e avaliação do potencial in vitro e in vivo contra Candida auris
• Beneficiário: Gabriel Davi Marena
• Modalidade de apoio: Bolsas no Brasil - Doutorado